Skip to main content

Table 1 Description of Patient Demographic Characteristics at the Index Date When SU or TZD Was Added to Prior Metformin Therapy

From: Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary

Characteristic All Patients
N = 414
SU* + MF
n = 341
TZD** + MF
n = 73
Age (mean yrs ± std) 60.5 ± 9.5 61.0 ± 8.9 57.9 ± 11.3
Female (%) 49.8% 49.0% 53.4%
Current Smokers (%) 13.5% 13.5% 13.7%
Zero alcohol consumption (%) 42.5% 43.1% 39.7%
Absence of Regular Physical Activity (%) 28.0% 28.7% 24.7%
Physical Activity 3–5 Times/Week (%) 11.6% 12.0% 9.6%
Height (mean cm ± std) 168.0 ± 8.7 168.0 ± 8.6 168.6 ± 9.3
Weight (mean kg ± std) 88.7 ± 15.5 88.5 ± 15.5 90.0 ± 15.4
BMI (mean ± std) 31.2 ± 4.7 31.2 ± 4.7 31.5 ± 4.8
H/O Micro-vascular Complications (%) 8.0% 8.5% 5.5%
H/O Macro-vascular Complications (%) 26.5% 25.8% 27.4%
Years since T2DM Diagnosis (mean yrs ± std) 6.6 ± 4.4 6.7 ± 4.4 6.2 ± 4.3
A1C Level (mean A1C ± std) 8.2 ± 1.5 8.3 ± 1.5 7.8 ± 1.2
  1. * SU: Sulfonylurea
  2. MF: Metformin
  3. ** TZD: Thiazolidinedione
  4. H/O: history of